{"publication_id":"4e5f3bb0-f06e-45a7-a244-efc65bf18284","screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["This receipt-backed scoping note has one bounded signal: mtor shows context-dependent, not convergent, associations across this 5-source primary/review bundle (2010-2024). Grouped by direction, directionally favorable: RAD001 improved influenza vaccine response by ~20% in the elderly; Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition... | other/mixed: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P =...; Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%). The source facts cover 5 population context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Concrete source-level examples: observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10; RAD001 improved influenza vaccine response by ~20% in the elderly; Patients treated with CNIs had a higher proportion of HCC within Milan criteria (74% vs. 69%).","other/mixed: International consensus on post-transplantation diabetes mellitus — observed no increase of 1-year PTDM versus CNI plus antiproliferative agents relative risk 1.16, 95% CI 0.97–1.38, P = .10","other/mixed: Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. — exhibit an approximately 20% increase in median survival."]}